CA3216026A1 - Triazine derivatives and their use in the treatment of cancer - Google Patents
Triazine derivatives and their use in the treatment of cancer Download PDFInfo
- Publication number
- CA3216026A1 CA3216026A1 CA3216026A CA3216026A CA3216026A1 CA 3216026 A1 CA3216026 A1 CA 3216026A1 CA 3216026 A CA3216026 A CA 3216026A CA 3216026 A CA3216026 A CA 3216026A CA 3216026 A1 CA3216026 A1 CA 3216026A1
- Authority
- CA
- Canada
- Prior art keywords
- amino
- methy1
- triazin
- phenol
- piperidyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21177660 | 2021-06-04 | ||
| EP21177660.4 | 2021-06-04 | ||
| EP21188639 | 2021-07-30 | ||
| EP21188639.5 | 2021-07-30 | ||
| EP21215875 | 2021-12-20 | ||
| EP21215875.2 | 2021-12-20 | ||
| PCT/EP2022/064995 WO2022253936A1 (en) | 2021-06-04 | 2022-06-02 | Triazine derivatives and their use in the treatment of cancer. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3216026A1 true CA3216026A1 (en) | 2022-12-08 |
Family
ID=82115763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3216026A Pending CA3216026A1 (en) | 2021-06-04 | 2022-06-02 | Triazine derivatives and their use in the treatment of cancer |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20240132471A1 (enExample) |
| EP (1) | EP4347571B1 (enExample) |
| JP (2) | JP7705963B2 (enExample) |
| KR (1) | KR20240019083A (enExample) |
| AR (1) | AR126053A1 (enExample) |
| AU (1) | AU2022287224A1 (enExample) |
| BR (1) | BR112023025318A2 (enExample) |
| CA (1) | CA3216026A1 (enExample) |
| CL (1) | CL2023003491A1 (enExample) |
| CO (1) | CO2023016212A2 (enExample) |
| CR (1) | CR20230566A (enExample) |
| DK (1) | DK4347571T3 (enExample) |
| ES (1) | ES3072832T3 (enExample) |
| FI (1) | FI4347571T3 (enExample) |
| HR (1) | HRP20260777T1 (enExample) |
| IL (1) | IL307201A (enExample) |
| LT (1) | LT4347571T (enExample) |
| MA (1) | MA64830B1 (enExample) |
| MX (1) | MX2023013998A (enExample) |
| PE (1) | PE20240928A1 (enExample) |
| RS (1) | RS68198B1 (enExample) |
| SM (1) | SMT202600264T1 (enExample) |
| WO (1) | WO2022253936A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| WO2022230912A1 (ja) | 2021-04-28 | 2022-11-03 | アステラス製薬株式会社 | 置換トリアジン化合物 |
| EP4347571B1 (en) * | 2021-06-04 | 2026-04-22 | F. Hoffmann-La Roche AG | Triazine derivatives and their use in the treatment of cancer. |
| MX2024008548A (es) * | 2022-01-07 | 2024-07-19 | Transthera Sciences Nanjing Inc | Inhibidor del inflamosoma nlrp3 y uso del mismo. |
| JP2025523930A (ja) * | 2022-07-21 | 2025-07-25 | エフ． ホフマン－ラ ロシュ アーゲー | Ｎｌｒｐ３阻害剤 |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| US20260167637A1 (en) * | 2022-11-04 | 2026-06-18 | Transthera Sciences (Nanjing), Inc. | Nlrp3 inflammasome inhibitor and use thereof |
| JP2025540202A (ja) * | 2022-12-07 | 2025-12-11 | エフ． ホフマン－ラ ロシュ アーゲー | Ｎｌｒｐ３阻害のモジュレーターとしての新規化合物 |
| EP4683918A1 (en) * | 2023-03-20 | 2026-01-28 | Insilico Medicine IP Limited | Nlrp3 inflammasome inhibitors and uses thereof |
| JP2026509587A (ja) * | 2023-03-23 | 2026-03-19 | 成都▲ざ▼▲霊▼生物医▲薬▼科技有限公司 | トリアジン化合物およびその使用 |
| CN120958000A (zh) * | 2023-04-19 | 2025-11-14 | 豪夫迈·罗氏有限公司 | 噁唑并[4,5-b]吡嗪和噁唑并[4,5-b]吡啶衍生物作为nlrp3抑制剂用于治疗例如炎症性疾病 |
| JP2026514799A (ja) * | 2023-04-19 | 2026-05-13 | エフ． ホフマン－ラ ロシュ アーゲー | 炎症性疾患の処置のためのｎｌｐｒ３阻害剤としての５－［５－（２－ヒドロキシフェニル）オキサゾロ［４，５－ｂ］ピリジン－２－イル］ピペリジン－２－オン誘導体 |
| AU2024280075A1 (en) | 2023-06-02 | 2025-12-11 | Merck Sharp & Dohme Llc | 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3 |
| CN121586712A (zh) * | 2023-07-28 | 2026-02-27 | 豪夫迈·罗氏有限公司 | 新颖化合物 |
| WO2025046419A1 (ko) * | 2023-08-25 | 2025-03-06 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法 |
| WO2025252772A1 (en) * | 2024-06-06 | 2025-12-11 | F. Hoffmann-La Roche Ag | Triazine derivatives |
| WO2026046981A1 (en) | 2024-08-28 | 2026-03-05 | F. Hoffmann-La Roche Ag | Solid forms of 5-[3-[[(3r)-1-ethyl-3-piperidyl]amino]-5-methyl-1,2,4-triazin-6-yl]-2,3- dihydrobenzofuran-4-ol |
| WO2026067453A1 (en) * | 2024-09-25 | 2026-04-02 | Insilico Medicine Ip Limited | Novel compounds as nlrp3 inflammasome inhibitors and uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020001425A (es) * | 2017-08-04 | 2020-08-06 | Skyhawk Therapeutics Inc | Metodos y composiciones para modular el empalme. |
| MX2020001776A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| BR112020019373A2 (pt) * | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
| US12168012B2 (en) | 2018-07-25 | 2024-12-17 | Novartis Ag | NLRP3 inflammasome inhibitors |
| WO2020163248A1 (en) * | 2019-02-04 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| BR112022014480A2 (pt) | 2020-01-22 | 2022-09-13 | Hoffmann La Roche | Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit |
| CN115279739B (zh) | 2020-03-27 | 2025-07-22 | 尼科治疗有限公司 | 取代哒嗪化合物 |
| TW202231281A (zh) | 2020-12-25 | 2022-08-16 | 大陸商上海拓界生物醫藥科技有限公司 | 一類含噠嗪的化合物及其醫藥用途 |
| EP4289823A4 (en) | 2021-02-08 | 2025-02-26 | Medshine Discovery Inc. | SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| WO2022230912A1 (ja) | 2021-04-28 | 2022-11-03 | アステラス製薬株式会社 | 置換トリアジン化合物 |
| EP4347571B1 (en) * | 2021-06-04 | 2026-04-22 | F. Hoffmann-La Roche AG | Triazine derivatives and their use in the treatment of cancer. |
| CN115433163A (zh) | 2021-06-05 | 2022-12-06 | 药捷安康(南京)科技股份有限公司 | Nlrp3炎症小体抑制剂及其应用 |
| PL4363406T3 (pl) | 2021-07-02 | 2026-01-05 | Astrazeneca Ab | Inhibitory inflamasomu nlrp3 |
| WO2023028536A1 (en) | 2021-08-25 | 2023-03-02 | Ptc Therapeutics, Inc. | 1,2,4-triazine derivatives useful as inhibitors of nlrp3 |
| WO2023066377A1 (zh) | 2021-10-22 | 2023-04-27 | 索智生物科技（浙江）有限公司 | 一种含氮化合物、其制备方法及应用 |
| MX2024008548A (es) | 2022-01-07 | 2024-07-19 | Transthera Sciences Nanjing Inc | Inhibidor del inflamosoma nlrp3 y uso del mismo. |
| KR20250005125A (ko) | 2022-03-25 | 2025-01-09 | 벤투스 테라퓨틱스 유에스 인코포레이티드 | NLRP3 유도체로서 유용한 피리도-[3,4-d]피리다진 아민 유도체 |
| CN120152974A (zh) | 2022-10-26 | 2025-06-13 | 天维生物制药有限公司 | 缩环哒嗪衍生物 |
| CN115621720B (zh) * | 2022-10-27 | 2026-07-07 | 永道射频技术股份有限公司 | 一种应用于rfid读写器的全息超材料阵列天线 |
| US20260167637A1 (en) | 2022-11-04 | 2026-06-18 | Transthera Sciences (Nanjing), Inc. | Nlrp3 inflammasome inhibitor and use thereof |
| US20260200914A1 (en) | 2022-12-28 | 2026-07-16 | Astrazeneca Ab | Nlrp3 inflammasome inhibitors |
| WO2024169858A1 (zh) | 2023-02-17 | 2024-08-22 | 成都赜灵生物医药科技有限公司 | 六元氮杂环类化合物及其用途 |
-
2022
- 2022-06-02 EP EP22731614.8A patent/EP4347571B1/en active Active
- 2022-06-02 RS RS20260704A patent/RS68198B1/sr unknown
- 2022-06-02 HR HRP20260777TT patent/HRP20260777T1/hr unknown
- 2022-06-02 MA MA64830A patent/MA64830B1/fr unknown
- 2022-06-02 FI FIEP22731614.8T patent/FI4347571T3/fi active
- 2022-06-02 JP JP2023572751A patent/JP7705963B2/ja active Active
- 2022-06-02 LT LTEPPCT/EP2022/064995T patent/LT4347571T/lt unknown
- 2022-06-02 CR CR20230566A patent/CR20230566A/es unknown
- 2022-06-02 BR BR112023025318A patent/BR112023025318A2/pt unknown
- 2022-06-02 AR ARP220101456A patent/AR126053A1/es unknown
- 2022-06-02 CA CA3216026A patent/CA3216026A1/en active Pending
- 2022-06-02 MX MX2023013998A patent/MX2023013998A/es unknown
- 2022-06-02 KR KR1020237039328A patent/KR20240019083A/ko active Pending
- 2022-06-02 DK DK22731614.8T patent/DK4347571T3/da active
- 2022-06-02 WO PCT/EP2022/064995 patent/WO2022253936A1/en not_active Ceased
- 2022-06-02 IL IL307201A patent/IL307201A/en unknown
- 2022-06-02 ES ES22731614T patent/ES3072832T3/es active Active
- 2022-06-02 PE PE2023003133A patent/PE20240928A1/es unknown
- 2022-06-02 SM SM20260264T patent/SMT202600264T1/it unknown
- 2022-06-02 AU AU2022287224A patent/AU2022287224A1/en active Pending
-
2023
- 2023-11-23 CL CL2023003491A patent/CL2023003491A1/es unknown
- 2023-11-29 CO CONC2023/0016212A patent/CO2023016212A2/es unknown
- 2023-11-30 US US18/524,678 patent/US20240132471A1/en not_active Abandoned
-
2025
- 2025-02-25 US US19/063,141 patent/US12421209B2/en active Active
- 2025-03-26 JP JP2025051003A patent/JP2025098157A/ja active Pending
- 2025-05-16 US US19/210,925 patent/US20250276958A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022287224A1 (en) | 2023-09-21 |
| CL2023003491A1 (es) | 2024-05-24 |
| EP4347571A1 (en) | 2024-04-10 |
| AR126053A1 (es) | 2023-09-06 |
| MA64830B1 (fr) | 2026-06-30 |
| US12421209B2 (en) | 2025-09-23 |
| WO2022253936A1 (en) | 2022-12-08 |
| CO2023016212A2 (es) | 2023-12-11 |
| CR20230566A (es) | 2024-01-22 |
| RS68198B1 (sr) | 2026-06-30 |
| BR112023025318A2 (pt) | 2024-02-27 |
| HRP20260777T1 (hr) | 2026-08-14 |
| TW202313577A (zh) | 2023-04-01 |
| JP2024522494A (ja) | 2024-06-21 |
| US20240132471A1 (en) | 2024-04-25 |
| MX2023013998A (es) | 2023-12-11 |
| SMT202600264T1 (it) | 2026-07-16 |
| KR20240019083A (ko) | 2024-02-14 |
| JP2025098157A (ja) | 2025-07-01 |
| EP4347571B1 (en) | 2026-04-22 |
| FI4347571T3 (fi) | 2026-06-17 |
| US20250276958A1 (en) | 2025-09-04 |
| DK4347571T3 (da) | 2026-06-29 |
| ES3072832T3 (en) | 2026-07-06 |
| US20250197370A1 (en) | 2025-06-19 |
| LT4347571T (lt) | 2026-07-10 |
| IL307201A (en) | 2023-11-01 |
| JP7705963B2 (ja) | 2025-07-10 |
| PE20240928A1 (es) | 2024-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4347571B1 (en) | Triazine derivatives and their use in the treatment of cancer. | |
| EP4337652B1 (en) | Nlrp3 inhibitors | |
| CN115485280A (zh) | 新三嗪并吲哚化合物 | |
| US20230203064A1 (en) | Tricyclic compounds as inhibitors of nlrp3 | |
| US20250353830A1 (en) | Novel compounds | |
| US20260015353A1 (en) | Novel compounds | |
| JP2025537238A (ja) | Ｎｌｒｐ３阻害剤としてのトリアジノン誘導体 | |
| EP4217347A1 (en) | New compounds | |
| WO2024121184A1 (en) | Inhibitors of nlrp3 | |
| TW202434581A (zh) | 新穎化合物 | |
| JP2025537237A (ja) | Ｎｌｒｐ３阻害剤としてのトリアジノン誘導体 | |
| CN117460718A (zh) | 三嗪衍生物及其在癌症的治疗中的用途 | |
| RU2861618C2 (ru) | Триазиновые производные и их применение в лечении рака | |
| EA052779B1 (ru) | Триазиновые производные и их применение в лечении рака | |
| HK40101872A (en) | Triazine derivatives and their use in the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250708 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250708 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260520 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260520 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260601 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260601 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260601 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260703 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260703 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260703 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260703 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260703 |